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lrich Gerckens, MD,* George Latsios, MD,* Ralf Mueller, MD,* Lutz Buellesfeld, MD,*
aniel John, MD,* Seyrani Yuecel, MD,* Barthel Sauren, MD,† Thomas Felderhof, MD,‡
tein Iversen, MD,‡ Eberhard Grube, MD*
iegburg, Germany
bjectives This study sought to assess post-procedural and mid-term outcome of patients, in which
second “in-series” CoreValve prosthesis (Medtronic, Minneapolis, Minnesota) was implanted during
he same procedure.
ackground Because of the increasing number of patients implanted with CoreValves, the need for
anagement of special complications has emerged. A misplaced prosthesis can be corrected by var-
ous maneuvers. An option is to pull the valve out of the aortic annulus into the ascending aorta or
eyond and position a second one (in series).
ethods Out of 277 patients who underwent CoreValve implantation with the 18-F device in our
nstitution, we had to implant a second prosthesis (due to severe aortic regurgitation or dislocation
f the ﬁrst one) in 9 (3.2%). Immediate post-procedural as well as mid-term follow-up data (5 to 20
onths, mean 10.6  6 months, total 95 patient-months) were collected for analysis.
esults All implantations of the second device were successful, resulting in elimination of the gra-
ient (mean gradient 43.14.0 mm Hg before to 7.0  1.1 mm Hg after implantation). There was
o ﬁnal aortic regurgitation grade 2. The extra-anatomically placed ﬁrst prosthesis (ascending
orta, n  8; abdominal aorta, n  1) did not cause any clinical sequelae or gradients. During mid-
erm follow-up, none of the 18 prostheses showed any sign of malfunction. Speciﬁcally, there were
o signs of valve migration or of worsening paravalvular regurgitation. No case of valve thrombosis
as documented.
onclusions A second CoreValve can be safely and effectively implanted in an in-series manner,
ithout periprocedural complications. No problems arose on mid-term follow-up, ranging up to
0 months. (J Am Coll Cardiol Intv 2010;3:244–50) © 2010 by the American College of Cardiology
oundation
rom the *Department of Cardiology/Angiology, †Department of Anesthesiology, and the ‡Department of Cardiothoracic
urgery, “Helios” Heart Center, Siegburg, Germany. Study devices provided by CoreValve. Drs. Grube and Gerckens are clinical
roctors for Medtronic.anuscript received August 17, 2009; revised manuscript received November 2, 2009, accepted November 13, 2009.
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245ince 2005 (1,2), transcatheter aortic valve implantation
TAVI) has gained acceptance as a therapeutic option for
atients with severe, symptomatic aortic stenosis and high
isk for conventional open heart surgery. Studies in multiple
enters have shown TAVI to be an effective and safe
rocedure in selected high-risk patients (3,4). The self-
xpandable CoreValve ReValving system (Medtronic, Min-
eapolis, Minnesota) is a Conformité Européenne–
pproved device and among the most widely used
echniques for transcatheter aortic valve implantation
6.000 implantations worldwide, data on file).
Because of this increasing number of patients treated with
CoreValve device, the need for management of specific
roblems has emerged. One of these problems is device
isplacement: too deep in the ventricle or too high within
he annulus. However, there are various correction maneu-
ers that can be used to optimize the device position
ncluding partial device retraction using a snare catheter or
mplantation of a second prosthesis either within the first
evice, or within the native annulus after retraction and
lacement of the first prosthesis within the ascending aorta
“in-series”) or even more distal segments such as the
bdominal aorta.
Out of 277 patients who underwent CoreValve implanta-
ion (Medtronic) with the 18-F device in our institution, in 9
3.2%), we pulled the fully deployed CoreValve prosthesis out
f its proper “anatomic” position, which is inside the native
alcified aortic valve, for correction of a suboptimal initial
evice placement followed by successful implantation of a
econd device.
In this report, we discuss the feasibility of this maneuver
nd on the immediate and mid-term (up to 2 years)
ollow-up of these 9 patients.
Table 1. Demographic Characteristics and Procedural Details of the Patien
Patient # Age (yrs) Sex Follow-Up Position of CVs
1 85 F 20 months 1st in asc aorta, 2nd normal P
2 83 M 18 months 1st in asc aorta, 2nd normal P
3 81 M 13 months 1st in asc aorta, 2nd normal P
4 52 M 12 months 1st in asc aorta, 2nd normal P
5 86 M 11 months 1st in asc aorta, 2nd normal P
6 78 F 10 months 1st in asc aorta, 2nd normal P
7 78 F 16 days 1st in asc aorta, 2nd normal P
8 88 M 6 months 1st in abdominal aorta,
2nd normal
P
9 78 F 5 months 1st in asc aorta, 2nd normal Pasc aorta ascending aorta; CVMedtronic CoreValve prosthesis.ethods
tudy design. This nonrandomized observational single-
enter retrospective study was conducted to evaluate the
afety and efficacy of implantation of a second CoreValve
rosthesis as a rescue maneuver, after a first misplaced
rosthesis was pulled out of the aortic annulus.
Procedural outcomes are reported and mid-term clinical,
chocardiographic, and fluoroscopic follow-up was performed.
atients and procedural details. Between July 2007 and
anuary 2009, 277 patients underwent elective CoreValve
rosthesis implantation with the third-generation 18-F
evice in our institution.
Procedural details of device implantation have been
escribed previously. In 9 of these patients (5 men, mean
ge 78.8 years) (Table 1), we implanted a second prosthesis
n the same session, because the first one was pulled out of
he aortic annulus either accidentally during the release
rocess or intentionally to correct suboptimal placement.
hese 9 patients were included in this analysis.
All patients provided written informed consent to un-
ergo the CoreValve TAVI procedure.
ollow-up. All patients received acetylsalicylic acid (100
g/day) before the procedure
nd lifelong afterward. Also, all
atients received clopidogrel
300-mg loading dose) 75 mg/
ay for 6 months. Platelet re-
ponsiveness to dual antiplatelet
herapy was tested, and if found
uboptimal, the daily dose of
lopidogrel was doubled.
planted With a Second In-Series CoreValve Prosthesis in Our Department
on for 2nd CV Comments CV Size Annulus Size (mm)
with catheter,
es not free
Vein grafts patent Small 22.5
with snare
deep)
Large 27.0
with catheter,
es not free
Vein grafts patent Large 27.3
with snare
deep)
Large 26.7
with snare
deep)
Large 24.8
with snare
deep)
Large 25.2
with snare
deep)
Died after right iliac artery
rupture and operation
Small 23.6
ith catheter Large 27.6
with snare (near
ain ostium)
Large 24.5
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
TAVI  transcatheter aortic
valve implantationts Im
Reas
ulling
hing
ulling
(too
ulling
hing
ulling
(too
ulling
(too
ulling
(too
ulling
(too
ulled w
ulling
left m
w
a
t
m
m
v
c
c
w
R
R
d
p
p
i
p
4
i
e
c
r
p
d
V
m
p
i
t
a
P
1
c
p
C
i
m
w
i
m
a
i
p
f
i
a
a
d
r
a
c
i
r
a
I
a
o
w
s
r
w
i
p
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 2 , 2 0 1 0
F E B R U A R Y 2 0 1 0 : 2 4 4 – 5 0
Gerckens et al.
2 In-Series CoreValves
246Clinical questioning and transthoracic echocardiography
ere performed after the procedure, at hospital discharge,
nd at 15 and 30 days after device implantation. Beyond
his, echocardiography and fluoroscopy were performed at 3
onth intervals: 3, 6, 12, and 18 months after implantation.
As adverse events, we considered death, serious arrhyth-
ia, neurological events, myocardial infarction, and any
alve structural deterioration. Deterioration was defined as
hanges intrinsic to the valve, such as wear, fracture,
alcification, leaflet tear, stent creep, or dislocation of the
hole or part of the porcine bioprosthetic tissue.
esults
etraction of the first prosthesis was accidental in 2 cases
uring device release or intentional due to suboptimal device
lacement in 7 cases. After retraction, the CoreValve
rosthesis was placed in the ascending aorta in 8 cases and
n the abdominal aorta in 1 case.
Implantation of the second device was successful in all 9
atients, resulting in a reduction of the mean gradient from
3.1  4.0 mm Hg before to 7.0  1.1 mm Hg after
mplantation, corresponding to an increase in calculated
ffective aortic valve area (Gorlin formula) from 0.62 0.05
m2 to 1.64  0.09 cm2 (Table 2). Resulting aortic
egurgitation was less than grade 2 in all cases. These
arameters were obtained by routine transthoracic echocar-
iography.
There was no hemodynamic gradient across the Core-
alve that was implanted extra-anatomically in all cases
easured invasively in the catheterization lab. None of the
atients were at any time hemodynamically unstable, nor
ntubated and mechanically ventilated.
In the case of placement in the abdominal aorta, due to
he unusual position of the prosthesis, this one was not
ccessible by echo for evaluation.
Specific details on the patients are as follows.
Table 2. Echocardiographic Evaluation of the Native Aortic Valve and of th
Patient #
P Mean (Before)
(mm Hg)
AVA (Before)
(cm2)
1 29 0.5
2 52 0.5
3 52 0.5
4 21 0.6
5 53 0.6
6 54 0.6
7* 38 0.9
8 52 0.7
9 37 0.8
Mean SD 43.1 4.0 0.62 0.05
*Patient died of vascular access complication.AR aortic regurgitation; AVA aortic valve area.rosthesis released in aorta (Patients #1, #3, and #8). Patient
was an 85-year-old woman, with a history of a former
oronary artery bypass graft (CABG) procedure and 3
atent vein grafts. It was not possible to release the first
oreValve from the delivery catheter, because the hinges on
ts upper part continued to keep it attached. Forceful
anipulation of both the delivery catheter and of the stiff
ire resulted in dislocation of the CoreValve in the ascend-
ng aorta.
Subsequently, while this prosthesis was kept stable by
eans of a snare catheter, the second prosthesis was
dvanced and successfully deployed. Noteworthy to this case
s the fact that all 3 vein aorto-coronary bypasses remained
atent (Fig. 1).
Patient #3 was an 81-year-old man, with a history of a
ormer CABG procedure with 2 vein grafts and a left
nternal mammary artery to left anterior descending
rtery graft. This case resembles that of Patient 1, as
gain the prosthesis could not be released from the
elivery catheter hinges, and forceful manipulation again
esulted in dislocation of the CoreValve in the ascending
orta.
We kept the prosthesis stable by means of a snare
atheter, and the second prosthesis was successfully
mplanted. Again, both vein aorto-coronary bypasses
emained patent (Fig. 2).
Patient #8 was an 88-year-old man with an aortic
nnulus of 27.6 mm estimated by computed tomography.
n his case, the prosthesis slid back completely in the
ortic root, at its left coronary cusp side, after deployment
f more than two-thirds. We initially attempted to pull it
ith the delivery catheter backward, through the 18-F
heath, and out of the body, in order to reload and
edeploy it. Again, this is a rather standard maneuver that
e have performed successfully several times. However,
n this specific case, as the almost completely deployed
rosthesis was pulled, some of the proximal struts exited
ropriately Placed CoreValve Prosthesis
P Mean (After)
(mm Hg)
AVA (After)
(cm2)
AR (After)
(1 to 4 Scale)
8 1.5 1.5
9 1.6 1.5
7 1.4 0.5
3 2.1 0.5
5 1.8 0.5
4 1.9 1.0
5 1.8 0.0
9 1.5 0.5
14 1.2 1.0
7.0 1.1 1.64 0.09 0.7 0.1e App
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247he delivery catheter, making its retrieval impossible. We
hen decided to “implant” it in the abdominal aorta,
elow the level of the renal arteries, and to further dilate
t with a balloon (Fig. 3). Then a second CoreValve was
dvanced in the usual manner and deployed uneventfully
n its correct position.
rosthesis pulled with a snare catheter (Patients #2, #4, #5,
6, #7, and #9). This refers to Patient #2, an 83-year-old
an; Patient #4, a 52-year-old man; Patient #5, an 86-year-
ld man; Patient #6, a 78-year-old woman; and Patient #7,
lso a 78-year-old woman, who share common procedural
haracteristics.
In all 5 of these patients, the CoreValve was implanted
oo deep, a fact that resulted in moderate-to-severe aortic
egurgitation. The decision was made to pull the prosthesis
y means of a snare catheter. A 15-mm loop snare catheter,
-F compatible (Amplatz Goose Neck Snare, ev3 Endovas-
ular, Inc., Plymouth, Minnesota), was introduced from the
-F femoral access site. The catheter was advanced to the
rosthesis hinges and was pulled under continuous hemo-
ynamic monitoring. The target was the normalization of
he diastolic aortic pressure and of the left ventricular
nd-diastolic pressure.
However, despite the fact that the specific maneuver had
een performed numerous times in our catheterization lab,
n these 5 cases, the result was the dislocation of the
oreValve prosthesis in the ascending aorta. We kept it
table by means of the snare catheter, and the second one
Figure 1. Patient #1 at the End of the 2 CoreValves Implantation
Aortographic image of section just above the correctly (at the aortic annu-
lus) positioned prosthesis. Note the 2 in-series CoreValves, the lack of dye
regurgitation in the left ventricle, and the patency of the vein bypass
(arrow) to the left coronary.as successfully implanted.Patient #7 unfortunately suffered a fatal complication.
fter closure of the right femoral artery with the Prostar XL
0 device (Abbott Vascular, Abbott Park, Illinois), the
rtery was occluded. The patient was operated on by a
ascular surgeon. She developed pneumonia and died of
ultiorgan failure 16 days later. Unfortunately, an
natomo-pathology report could not be obtained, because
he relatives did not give their permission for an autopsy to
e performed.
In Patient #9, a 78-year-old woman, the CoreValve
rosthesis was deployed near the left main coronary artery
stium. Although the blood flow in the left system was not
ompromised, we decided to pull it out of this position. By
eans of a snare catheter, initially unsuccessfully from the
emoral artery and consequently successfully from the left
rachial artery, the prosthesis was pulled and stabilized in
he ascending aorta, distal to the aortic arch arterial
ranches. Subsequently, while the first CoreValve was kept
table by means of the snare catheter, a second CoreValve
as advanced and successfully deployed.
All 9 patients underwent the procedure of the second
alve implantation without any significant sequels. The
rocedural time was prolonged by a mean of 35  9 min.
ith the exception of Patient #7, who was operated upon
y a vascular surgeon in the catheterization lab and needed
ransfusion of 2 U of packed red cells, all other patients
Figure 2. Patient #3 at 1-Year Follow-Up
Multislice cardiac computer tomography (16  0.75 mm) showing the 2
CoreValve prostheses, 1 transannularly (white arrow) and 1 at the ascend-
ing aorta (black arrow).
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248id not receive any transfusions (Table 2, asterisk marked
atient).
We experienced no periprocedural complications in any
f the patients after the implantation of the second pros-
hesis, in-series to the misplaced one. The misplaced Core-
alve functioned normally, from a hemodynamic point of
iew, as a valve conduit inside the aorta, and showed
omplete apposition against the aortic wall.
The follow-up period on the patients (Table 1) ranged
rom 5 to 20 months (mean 10.6  6.1 months; median 11
onths). Two patients were followed for a period of more
han 1.5 years, another 4 for almost 1 year and the
emaining 2 for 6 months.
In total, 95 patient-months in follow-up were available for
nalysis. During this period, none of the 18 devices showed any
ign of malfunction, especially none of the 9 that were
xtra-anatomically positioned. More specifically, during echo
nd fluoroscopy follow-up, there were no signs of valve
igration or of new onset paravalvular regurgitation. No case
f valve thrombosis was documented.
Structural valve deterioration was also not observed in any
f the patients. Also, no cases of embolism were reported,
ither thrombotic or of other origin.
iscussion
ince its introduction, and especially after Conformité
Figure 3. Patient #8 at End of the 2 CoreValves Implantation and Follow-U
(A) At the end of the 2 CoreValves implantation and (B) at 6-month follow-up
above the displaced CoreValve prosthesis. Note the infra-renal position of the
proximal part of the prosthesis (black arrow). (B) Fluoroscopic control of the
tion of the prosthesis (black arrow). Note the position of the CoreValve relevauropéenne approval in February 2007, the number ofatients treated by TAVI with the CoreValve ReValving
echnology has risen to over 4,000 worldwide. As our
nowledge of the procedure’s particularities expand, the
eed for management of special complications emerges. A
isplaced prosthesis is such a complication and can be dealt
ith by various maneuvers.
A technical point worth mentioning is the way that the
rosthesis moves “deeper,” that is, toward the left ventricle.
hen half deployed, it moves by itself in this direction,
ecause of its tendency to occupy the largest available space.
onstant pull on the delivery catheter and pushing of the
ent stiff wire against the ventricular apex are used to avoid
“too deep” implantation. Caution should be used, because
fter its deployment, the prosthesis can no longer be moved
n this direction.
Movement in the other direction, which is “shallower”
oward the aortic root, can be accomplished in the following
ways.
. At the end of the deployment, but before the final release
from the catheter’s hinges, if the CoreValve prosthesis is
too deep, it can be pulled proximally to its correct
position by steadily pulling on the catheter.
. Also, after its release, pulling a deeply deployed prosthe-
sis can be accomplished. A snare catheter, 6-F compat-
ible (Amplatz Goose Neck Snare) is inserted through the
femoral or brachial arteries. The specific snare catheter
antero-posterior projections. (A) Aortographic image of the abdominal aorta,
esis, the patent renal arteries (white arrows), and the slightly deformed
alve prosthesis in the abdominal aorta. No displacement or further deforma-
the vertebrae.p
. Both
prosth
CoreVhas the advantage of a loop configuration, enabling easier
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249engagement to the prosthesis hinges. Our personal
preference is to initially introduce the snare catheter from
the femoral artery, through the existing arterial access
site. This was the case in all 6 patients of this study, in
which we performed this maneuver. The snare subse-
quently engages 1 of the 2 prosthesis hinges and constant
pulling force is employed. As already stated, target is the
normalization of the diastolic aortic pressure.
In cases where pulling from the femoral artery is unsuc-
essful, we then proceed with snaring from the brachial
rtery. The decision to use left versus right brachial artery
epends mainly on the direction we wish to perform the
ulling. Due to the limited experience, no solid recommen-
ation can be further given.
Implantation of a second CoreValve prosthesis is some-
imes the only measure left to the interventionalist perform-
ng TAVI in order to avoid open-heart emergency surgery
r circulatory collapse. The second valve can be within the
rst (“valve-in-valve” concept). Another option is to pull
snare) the first higher in the ascending aorta and deploy a
econd in the correct anatomic position. This maneuver can
lso be carried out in cases when the prosthesis is acciden-
ally withdrawn from the aortic annulus. Although the
heoretical issue of aortic perforation by pulling the device
an be raised, we do not consider it significant, as was also
roven in this study (pulling uneventful in 6 of 6 patients).
owever, the operator should check the direction of the
ulling, so that the hinges do not traumatize the aortic wall,
nd also check that the deformation of the aortic arch is not
evere during the maneuver.
In 2 patients, the delivery catheter would not disengage
he CoreValve hinges. Although this is a very rare occur-
ence, operator should always verify the release of the
rosthesis. This is made fluoroscopically obvious when the
atheter’s distal part is some distance from the hinges.
therwise, small back and forth movements of the catheter
nable release of the CoreValve prosthesis.
After unsuccessful TAVI due to CoreValve misplace-
ent, whether to put a new valve inside the first or pull the
rst one to another aortic location and implant a second in
“single strut layer” way, depends on operator preferences
nd sometimes on special procedural circumstances.
A second valve inside the already implanted valve is a
easible option and has been performed not only in our
nstitution but also by others with procedural (5) as well as
ong-term (6) success.
Nevertheless, 2 valves in the same, or near same, ana-
omic position, partially overlapping each other, have the
ollowing disadvantages.
First, the amount of metal (nitinol) residing against the
ative aortic wall is doubled, and this way the time required
or endothelialization is prolonged. By our approach, the Vecond prosthesis is implanted in series, so less metal is
pposed to the wall.
Second, when 2 valves are implanted in close, but not
omplete, overlapping, the total size of the “skirt” is in-
reased to more than the normal 1.2 cm. This increases the
isk of covering the native coronary ostia. This is especially
rue in patients who have not undergone a CABG proce-
ure and are totally dependent on a native coronary blood
upply. Recommendations for exact placement of the device
ave been discussed elsewhere (7). When pulled and sub-
equently implanted in the ascending aorta, the prosthesis
id not cause any vein bypass obstruction in those patients
ho had undergone a CABG procedure.
Third, a too deeply implanted CoreValve, causing aortic
nd mitral regurgitation, cannot be left in place. A second
alve-in-valve prosthesis can resolve the issue with the aortic
egurgitation. However, the mitral regurgitation caused by
he initially misplaced prosthesis will remain, unless this
rosthesis is removed away from the mitral apparatus.
For these reasons, we suggest that a CoreValve too deeply
eated should be snared to its proper position. If this causes
he prosthesis to be dislocated above the aortic annulus, or
f the prosthesis is initially positioned in a supra-annular
osition, the following course of action is recommended.
his prosthesis is captured with a snare, through the femoral
ccess or preferably through the left or right brachial access,
nd pulled to the ascending aorta, just below the origin of the
ain vessel trunks.
While constantly kept there by continuous pulling, a second
rosthesis is advanced and positioned in the usual manner. This
aneuver was successful in all 9 patients that we treated.
In this study, we demonstrated that 2 CoreValves can be
afely and effectively implanted in an in-series manner,
ithout periprocedural complications. This way, the need
or surgery is avoided, making TAVI a pure interventional
rocedure. Also, on follow-up, extending to 1.5 years, no
roblems arose due to the second prosthesis. We did not
xperience either periprocedural complications after the
mplantation of the second prosthesis, or any events in
ollow-up due to the misplaced CoreValve. The latter
unctioned normally, from a hemodynamic point of view, as
valve conduit inside the aorta and showed complete
pposition against the aortic wall.
In the 18-F Expanded Evaluation Registry of 646 pa-
ients, a second valve was implanted in 2.6% of the patients
8). The distinction between a valve-in-valve or sequential
alve implantation was not made. Similarly, the rate of a
alve-in-valve procedure was 2% in a study of 86 patients
mplanted with the 21- or 18-F CoreValve ReValving
ystem prosthesis from our center (4), and at 9.6% in
nother experienced center (7). In our experience, dedicated
o the 18-F size system since July 2007, we report an
ncidence of 3.2% of patients receiving a second Core-
alve prosthesis. Possible explanations for the discrepancy
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250nclude: 1) center-specific results; and 2) differing thresholds
or implantation of a second valve.
Our patients were followed for up to 20 months, for a
otal of 95 patient-years. During this period, none of the
evices showed any sign of malfunction, migration, or
tructural deterioration. The 2 in-series CoreValve prosthe-
es showed no adverse clinical or hemodynamic sequelae.
onclusions
e demonstrated that 2 CoreValve prostheses can be safely
nd effectively implanted as a rescue maneuver in an
n-series manner, without periprocedural complications.
This second prosthesis caused no problems on mid-term
ollow-up.
eprint requests and correspondence: Dr. George Latsios,
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